Veru targets Q1 2027 PLATEAU interim analysis after enrolling 239 patients (NASDAQ:VERU)
Veru (VERU) Q3 FY2026 earnings call: PLATEAU Phase IIb enrollment, Q1 2027 interim catalyst, Novo Wegovy deal, patents to 2044, cash runwayâread now.
YayaNews contributes financial news and market context through the YayaNews editorial workflow.
Veru (VERU) Q3 FY2026 earnings call: PLATEAU Phase IIb enrollment, Q1 2027 interim catalyst, Novo Wegovy deal, patents to 2044, cash runwayâread now.
Veru targets Q1 2027 PLATEAU interim analysis after enrolling 239 patients (NASDAQ:VERU) | Seeking Alpha
Earnings Call Insights: Veru Inc. (VERU) Q3 fiscal 2026
Management view
Dr. Mitchell Steiner said Veru is focused on two small molecules, with near-term emphasis on enobosarm in obesity: enobosarm is being developed âas a next-generation drug that when combined with a GLP-1 receptor
Seeking Alpha's Disclaimer:
This article was automatically generated by an AI tool based on content available on the Seeking Alpha website, and has not been curated or reviewed by humans. Due to inherent limitations in using AI-based tools, the accuracy, completeness, or timeliness of such articles cannot be guaranteed. This article is intended for informational purposes only. Seeking Alpha does not take account of your objectives or your financial situation and does not offer any personalized investment advice. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank.
To ensure this doesnât happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please
report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.
Search field
Entering text into the input field will update the search result below
Quick Insights
What are the key catalysts for Veruâs near-term value in obesity drug development?
The fully enrolled Phase IIb PLATEAU trial with interim (32-week) data expected soon, partnerships such as the Novo Nordisk Wegovy agreement, and the issuance of key IP/patents.
How do Veruâs financial health and funding runway impact the risk profile?
Veru has negative cash flow, is not profitable, but reports sufficient cash to fund operations beyond the PLATEAU trialâs interim readout according to current plans.
What is the strategic significance of Veruâs intellectual property and Novo Nordisk agreement for future commercialization?
Veru gained a broad patent allowance for enobosarm with all weight-loss drugs, has a patent extending to at least 2044, and secured a Novo Nordisk Wegovy supply agreement with right of first negotiation, strengthening IP and commercial positioning.
Recommended For You
More
Trending News
See More
»
Original YayaNews editorial coverage, published for informational purposes.
This article is sourced from Seeking Alpha. It is for informational purposes only and does not constitute investment advice.
Topics & Symbols
Continue Reading
Related Reading
Imperial Brands prepares for a round of job cuts in Europe and the U.S. (IMBBY:OTCMKTS)
Imperial Brands (IMMBY) plans major U.S./Europe job cuts to lower costs amid falling cigarette demand.
Post-Market Earnings: Tech and Consumer Diverge as Profit Bottom May Be Near
After Monday's close, major companies reported earnings showing strong AI demand but cost pressures in tech, resilient yet divergent consumer spending, and easing energy costs. Markets focus on earnings quality and rate cut expectations, with CPI and bank results ahead.
Vertical Aerospace Secures ~$100M to Accelerate Valo Certification and Commercialization, Shares Rebound
Vertical Aerospace announced ~$100 million in new funding to support Valo eVTOL certification and commercialization. The company's shares rebounded amid intensifying industry competition, with investors closely watching certification milestones.
Bowman Consulting to be taken private by Bernhard for $43/share (BWMN:NASDAQ)
Bowman Consulting (BWMN) to be acquired by Bernhard Capital for $43/share cash (~$1B EV), a ~58% premium; deal targets Q4 2026âQ1 2027.